Fate Therapeutics, Inc.
FATE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | 0.10 | 0.02 | -0.09 |
| FCF Yield | -17.73% | -19.55% | -37.43% | -14.35% |
| EV / EBITDA | -5.43 | -5.61 | -3.48 | -5.77 |
| Quality | ||||
| ROIC | -10.84% | -10.43% | -10.95% | -15.08% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.76 | 0.72 | 0.90 | 0.53 |
| Growth | ||||
| Revenue 3-Year CAGR | -59.35% | -58.59% | -53.99% | -47.88% |
| Free Cash Flow Growth | -2.42% | 25.87% | -25.48% | 6.74% |
| Safety | ||||
| Net Debt / EBITDA | -1.11 | -1.30 | -1.01 | -1.17 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 35.26 | 65.84 | 132.93 | 171.24 |